Industry Roundup: FPLA changes; Nutroganics in soy market; spiked product, supplement-beverage warnings; Kamil chairs CRN
This article was originally published in The Tan Sheet
Executive Summary
FPLA changes proposed; Nutroganics invests to reach soy market; Shoreside hits spiked ingredient trifecta; NYSW blurs supplement-beverage line; Kamil elected CRN chair; and more news in brief.
You may also be interested in...
Relaxation Potion Warning: Wake Up Call About FDA Beverage Guidance
FDA warning letter on Dewmar’s Lean Slow Motion…Potion line is the first addressing differences between products marketed as conventional beverages and as liquid supplements since a final guidance in January. Attorney Justin Prochnow says the warning could signal an FDA crackdown on melatonin in conventional beverages.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.